Target type: biologicalprocess
Any process that stops, prevents or reduces the frequency, rate or extent of GDF15-GFRAL signaling pathway. [PMID:35177851]
Negative regulation of GDF15-GFRAL signaling pathway involves a complex interplay of molecular mechanisms that modulate the activity of GDF15, its receptor GFRAL, and downstream signaling cascades. This process plays a crucial role in maintaining cellular homeostasis and preventing aberrant cell growth and proliferation.
**1. GDF15 Production and Secretion:** GDF15, a member of the transforming growth factor-beta (TGF-beta) superfamily, is primarily produced by various cell types in response to cellular stress, such as hypoxia, oxidative stress, and inflammation.
**2. GDF15-GFRAL Interaction:** GDF15 binds to its specific receptor, GFRAL, a transmembrane protein expressed on various cell types. This binding initiates signal transduction, ultimately leading to the activation of intracellular signaling pathways.
**3. Negative Regulation Mechanisms:**
* **Inhibition of GDF15 Production:** Factors that suppress GDF15 synthesis can negatively regulate the pathway. For instance, certain growth factors and cytokines can downregulate GDF15 gene expression, thereby reducing its availability for signaling.
* **Blocking GDF15-GFRAL Interaction:** Molecules that interfere with the binding of GDF15 to GFRAL can disrupt signaling. These may include:
* **Soluble GFRAL:** This secreted form of GFRAL acts as a decoy receptor by competing with cell surface GFRAL for GDF15 binding.
* **Antibodies:** Antibodies targeting GDF15 or GFRAL can block their interaction, inhibiting signal transduction.
* **Downstream Signal Inhibition:** Components of the downstream signaling pathways activated by GDF15-GFRAL interaction can be negatively regulated. This may involve:
* **Phosphatases:** Enzymes that remove phosphate groups from signaling proteins, thereby deactivating them.
* **Inhibitory Proteins:** Specific proteins that bind to and inactivate signaling molecules, such as kinases or transcription factors.
* **MicroRNAs:** Small non-coding RNAs that target and suppress the expression of mRNAs involved in GDF15-GFRAL signaling.
**4. Consequences of Negative Regulation:** Decreased GDF15-GFRAL signaling can lead to:
* **Reduced Cellular Stress Responses:** By dampening the signal initiated by GDF15, cells may become less responsive to stress conditions, potentially leading to cellular dysfunction or death.
* **Enhanced Cell Growth and Proliferation:** The negative regulation of the pathway can promote cell division and proliferation, which may be beneficial in certain contexts but can also contribute to tumorigenesis if uncontrolled.
* **Altered Metabolic Processes:** GDF15-GFRAL signaling is implicated in metabolic regulation, and its negative modulation can affect energy expenditure, glucose metabolism, and appetite control.
**In summary, negative regulation of GDF15-GFRAL signaling is a critical process for maintaining cellular homeostasis and ensuring appropriate responses to various stimuli. Disruption of this pathway can lead to various pathological conditions.**'"
Protein | Definition | Taxonomy |
---|---|---|
Matrix metalloproteinase-14 | A matrix metalloproteinase-14 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P50281] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
tiludronic acid | tiludronic acid: a bone resorption inhibitor; an antihypercalcemic agent; used in the tratment of Paget's disease; used in the treatment and prevention of osteoporosis; structure given in first source | organochlorine compound | |
epigallocatechin gallate | (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin. epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis) | flavans; gallate ester; polyphenol | antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite |
zoledronic acid | zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position. Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS. | 1,1-bis(phosphonic acid); imidazoles | bone density conservation agent |
marimastat | marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide. marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary | hydroxamic acid; secondary carboxamide | antineoplastic agent; matrix metalloproteinase inhibitor |
ilomastat | CS 610: matrix metalloproteinase inhibitor; structure in first source ilomastat : An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor | hydroxamic acid; L-tryptophan derivative; N-acyl-amino acid | anti-inflammatory agent; antibacterial agent; antineoplastic agent; EC 3.4.24.24 (gelatinase A) inhibitor; neuroprotective agent |
cgs 27023a | CGS 27023A: a matrix metalloproteinase inhibitor | ||
prinomastat | prinomastat : A hydroxamic acid that is (3S)-N-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide in which the hydrogen attached to the thiomorpholine nitrogen has been replaced by a [4-(pyridin-4-yloxy)phenyl]sulfonyl group. It is a selective inhibitor with of matrix metalloproteinases (MMPs) 2, 3, 9, 13, and 14. prinomastat: a diazepine-based hydroxamic acid inhibitor; matrix metalloproteinase (MMP) inhibitor; angiogenesis inhibitor; | aromatic ether; hydroxamic acid; pyridines; sulfonamide; thiomorpholines | antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor; matrix metalloproteinase inhibitor |
rs-130830 | RS-130830: orally-active broad-spectrum matrix metalloproteinase inhibitor | ||
tmi-1 | |||
batimastat | batimastat : A secondary carboxamide resulting from the formal condensation of the carboxy group of (2S,3R)-5-methyl-3-{[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-[(thiophen-2-ylsulfanyl)methyl]hexanoic acid with the amino group of hydroxylamine. It a broad-spectrum matrix metalloprotease inhibitor. batimastat: structure given in first source; a synthetic matrix metalloproteinase inhibitor | hydroxamic acid; L-phenylalanine derivative; organic sulfide; secondary carboxamide; thiophenes; triamide | angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor |
ik 682 | IK 682: inhibits TNF-alpha converting enzyme; structure in first source | hydroxamic acid; pyrrolidin-2-ones; quinolines | |
epigallocatechin-3-o-(3''-o-methyl)-gallate | catechin | ||
ro 32-3555 | Ro 32-3555: structure given in first source | ||
sb 3ct compound | SB 3CT compound: a matrix metalloproteinase-2 inhibitor; structure in first source | aromatic ether | |
pd 166793 | |||
sc 78080 | |||
ro 31-9790 | Ro 31-9790: hydroxamic acid derivative | ||
arp-100 | |||
kb r8301 | |||
N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide | N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide : A hydroxamic acid that is N-hydroxy-D-valinamide in which the alpha-amino group has been substituted by isopropoxy and [biphenyl]-4-ylsulfonyl groups. A selective matrix metalloproteinase-2 (MMP-2) inhibitor, it is one of the most potent inducers of autophagy. Its physiological roles include angiogenesis, cancer metastasis, embryogenesis, tissue remodeling in development, and wound healing. | D-valine derivative; hydroxamic acid | antineoplastic agent; autophagy inducer; EC 3.4.24.24 (gelatinase A) inhibitor; melanin synthesis inhibitor |
bms-566394 | BMS-566394: structure in first source | ||
incb3619 | INCB3619: ADAM inhibitor; structure in first source | ||
6-(3,5-difluoroanilino)-9-ethyl-2-purinecarbonitrile | 6-aminopurines | ||
6-(3,5-difluoroanilino)-9-(2,2-difluoroethyl)-2-purinecarbonitrile | 6-aminopurines | ||
9-(3,5-difluorophenyl)-6-(ethylamino)-2-purinecarbonitrile | imidazoles | ||
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source |